GMED Stock Recent News

GMED's fourth-quarter 2024 performance reflects strong synergies from the NuVasive merger.

Globus Medical, Inc. (NYSE:GMED ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Brian Kearns - SVP, Business Development and IR Daniel Scavilla - President and CEO Keith Pfeil - COO and CFO Conference Call Participants Vik Chopra - Wells Fargo Matt Miksic - Barclays David Saxon - Needham & Company Jason Wittes - ROTH Shagun Singh - RBC Caitlin Cronin - Canaccord Genuity Craig Bijou - Bank of America Securities Matthew O'Brien - Piper Sandler Steve Lichtman - Oppenheimer Ryan Zimmerman - BTIG Matthew Blackman - Stifel Operator Welcome to the Globus Medical's Fourth Quarter and Full Year 2024 Earnings Call. This time, all lines will be on mute and a Q&A session will be held after the prepared remarks.

While the top- and bottom-line numbers for Globus Medical (GMED) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Globus Medical (GMED) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.60 per share a year ago.

Medical technologies specialist Globus Medical (GMED 0.04%) reported impressive results for the fourth quarter of 2024 on Thursday, Feb. 20. The highlights included adjusted earnings per share (EPS) of $0.84, exceeding the consensus forecast of $0.75, along with revenue that reached $657.3 million, topping expectations by $12.3 million.

AUDUBON, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2024.

Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GMED is set to acquire all shares of Nevro in an all-cash transaction, unlocking new growth opportunities.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSE: NVRO) to Globus Medical, Inc. (NYSE: GMED). Under the terms of the proposed transaction, shareholders of Nevro will receive $5.85 in cash for each share of Nevro that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the.